viewArix Bioscience PLC

Arix Bioscience has “multiple shots on goal”, ShoreCap initiates as a ‘buy’

The stockbroker highlights that with 12 core investments there are multiple chances in the portfolio for success.

Arix Bioscience PLC - Arix Bioscience has “multiple shots on goal”, ShoreCap rates as a ‘buy’
ShoreCap is the latest City firm to have an upbeat view on Arix

Arix Bioscience PLC (LON:ARIX) has been initiated as a ‘buy’ by analysts at stockbroker Shore Capital, in a note highlighting that the growing biotech investor has “multiple shots on goal”.

The venture-capital style firm, which invests in potentially disruptive life sciences businesses, plays an active role in the companies it backs and a number of those are now advancing high potential opportunities.

Specifically, according to Shore Capital, the firm’s core investments are across twelve companies giving investors exposure to a £168mln portfolio – plus, Arix’s own £60mln of cash in the bank.

“The biotech portfolio is invested across 12 core companies, focused on cancer, immunology & inflammation, rare diseases/gene therapy and anti-infectives and a ‘Discovery’ portfolio of earlier stage assets,” Shore Cap analyst Dr Tara Raveendran said in the note to clients.

The analyst added: “Led by an impressive team with a breadth of industry experience, strong industry partners (Takeda, Ipsen, UCB and Fosun) and close relationships with leading universities and academic institutes, Arix is an attractive vehicle for investors and a compelling strategic and financial partner for portfolio companies.”

ShoreCap is not the only City firm taking an upbeat view. Earlier this month, Jefferies suggested the London listed share could double in value as it gave a ‘buy’ recommendation and a 229p price target following Arix’s capital markets day at the stock exchange.

Looking at the group’s market valuation versus assets, Jefferies said: “The current 31% discount is cheap in our view and allows no value for Arix's private assets.”

The potential held within the Arix portfolio was more recently underlined on 16 October when “portfolio company” Aura Biosciences revealed its lead candidate for an eye cancer treatment had shown “early signs of efficacy” in a Phase 1b/2 clinical trial.

It is one of a number of positive developments recently supporting the investment group’s share price.

Quick facts: Arix Bioscience PLC

Price: 101.0001 GBX

Market: LSE
Market Cap: £137.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...


Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up. Britain’s biggest sports retailer...

2 weeks ago

2 min read